Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke . Usual treatment is to use low molecular weight heparin followed by vitamin K antagonists Other studies have shown that the new oral anticoagulants with or without initial heparin are effective alternatives. The endoxaban is a direct Factor Xa<a href="https://solaci.org/en/2015/06/24/hokusai-vte-endoxaban-shows-solid-results-versus-warfarin-in-venous-thromboembolism/" title="Read more" >...</a>

Aspirin, Clopidogrel and Warfarin. Is it safe or is a triple scheme necessary?

Original title: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Reference: Dewilde WJ et al. Lancet. 2013 Mar 30;381(9872):1107-15 The question to answer was simple, relevant, and is increasingly frequent in everyday practice: what to do when a patient who is anticoagulated has<a href="https://solaci.org/en/2013/05/10/aspirin-clopidogrel-and-warfarin-is-it-safe-or-is-a-triple-scheme-necessary/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Acute Pulmonary Thromboembolism: When Anticoagulation Alone May Not Be Enough

In recent times, pulmonary thromboembolism (PTE) has been the subject of growing research due to its persistent impact on morbidity and mortality. Acute PTE, if not properly treated or inadequately treated, can lead to a debilitating condition known as post-PTE syndrome, which has been documented in nearly 50% of survivors. The primary treatment strategy for<a href="https://solaci.org/en/2023/11/08/acute-pulmonary-thromboembolism-when-anticoagulation-alone-may-not-be-enough/" title="Read more" >...</a>

TCT 2023 | The WATCH-TAVR Study

In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting anticoagulant treatment, especially with oral anticoagulants (VKAs), primarily due to bleeding. The purpose of this study was to assess the feasibility, safety, and efficacy of combined<a href="https://solaci.org/en/2023/10/27/tct-2023-the-watch-tavr-study/" title="Read more" >...</a>

El cierre de orejuela es seguro con los nuevos dispositivos

Left Atrial Appendage Closure: As Effective in Men and Women?

Atrial fibrillation is the most prevalent arrhythmia and to prevent its potential complications, we should administer anticoagulants (OACs), either warfarin or the new direct oral anticoagulants (DOACs).  Even though these drugs have been shown effective, they still involve the risk of bleeding, especially gastrointestinal bleeding, which in turn leads to numerous hospitalizations. Left atrial appendage occlusion<a href="https://solaci.org/en/2023/08/18/left-atrial-appendage-closure-as-effective-in-men-and-women/" title="Read more" >...</a>

Leak periprotésico en cierre de orejuela, algo más que un valor para tener en cuenta

Peridevice Leak in Left Atrial Appendage Closure: more than one value to take into account

According to several registries, incomplete left atrial appendage (LAA) closure has been observed in up to 30% of cases after device implantation. The main cause of this complication is a mismatch between closure device and LAA ostium. The latter is elliptical in shape and varies in length, while the Watchman LAA closure device is round<a href="https://solaci.org/en/2022/07/29/peridevice-leak-in-left-atrial-appendage-closure-more-than-one-value-to-take-into-account/" title="Read more" >...</a>

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in the PROTECT-AF and PREVAIL studies, reduced risk of atrial fibrillation driven stroke, by excluding the left atrial appendage form systemic circulation.  Both studies used post procedure standardized protocols involving followup at 45 days and 6 months, imaging, and<a href="https://solaci.org/en/2022/07/15/antithrombotic-therapy-post-percutaneous-left-atrial-appendage-closure/" title="Read more" >...</a>

Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?

Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding. One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed. Researchers conducted an analysis of the National<a href="https://solaci.org/en/2022/04/25/should-we-use-left-atrial-appendage-occlusion-more-frequently-what-real-life-data-are-available/" title="Read more" >...</a>

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long term to prevent major cardiovascular, neurological, or bleeding events. Moreover, procedures not related to prosthesis implantation saw significant reduction. The PRAGUE-17 was a randomized non-inferiority study comparing left atrial appendage closure (Watchman or Amulet) with direct anticoagulants (95%<a href="https://solaci.org/en/2022/01/14/left-atrial-appendage-closure-vs-direct-anticoagulants-at-long-term/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>